Kilitch Drugs (India) Limited - Asset Resilience Ratio

Latest as of September 2025: 21.83%

Kilitch Drugs (India) Limited (KILITCH) has an Asset Resilience Ratio of 21.83% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KILITCH net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Rs870.13 Million

≈ $9.41 Million USD Cash + Short-term Investments

Total Assets

Rs3.99 Billion

≈ $43.11 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Kilitch Drugs (India) Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see KILITCH asset base.

Liquid Assets Composition Over Time

This chart breaks down Kilitch Drugs (India) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore KILITCH long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs330.90 Million	8.3%
Short-term Investments	Rs539.23 Million	13.53%
Total Liquid Assets	Rs870.13 Million	21.83%

Asset Resilience Insights

Good Liquidity Position: Kilitch Drugs (India) Limited maintains a healthy 21.83% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Kilitch Drugs (India) Limited Industry Peers by Asset Resilience Ratio

Compare Kilitch Drugs (India) Limited's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Kilitch Drugs (India) Limited (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Kilitch Drugs (India) Limited.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	16.77%	Rs524.66 Million ≈ $5.67 Million	Rs3.13 Billion ≈ $33.83 Million	-8.51pp
2024-03-31	25.28%	Rs606.88 Million ≈ $6.56 Million	Rs2.40 Billion ≈ $25.96 Million	+7.30pp
2023-03-31	17.98%	Rs394.65 Million ≈ $4.27 Million	Rs2.20 Billion ≈ $23.74 Million	-4.53pp
2022-03-31	22.51%	Rs472.34 Million ≈ $5.11 Million	Rs2.10 Billion ≈ $22.69 Million	+4.59pp
2021-03-31	17.92%	Rs364.00 Million ≈ $3.94 Million	Rs2.03 Billion ≈ $21.97 Million	-1.56pp
2020-03-31	19.47%	Rs278.10 Million ≈ $3.01 Million	Rs1.43 Billion ≈ $15.45 Million	-0.31pp
2019-03-31	19.78%	Rs284.16 Million ≈ $3.07 Million	Rs1.44 Billion ≈ $15.54 Million	-7.69pp
2018-03-31	27.47%	Rs350.66 Million ≈ $3.79 Million	Rs1.28 Billion ≈ $13.81 Million	+2.37pp
2017-03-31	25.09%	Rs283.30 Million ≈ $3.06 Million	Rs1.13 Billion ≈ $12.21 Million	+5.28pp
2016-03-31	19.82%	Rs231.21 Million ≈ $2.50 Million	Rs1.17 Billion ≈ $12.62 Million	+0.35pp
2015-03-31	19.47%	Rs246.69 Million ≈ $2.67 Million	Rs1.27 Billion ≈ $13.71 Million	-10.88pp
2014-03-31	30.34%	Rs391.63 Million ≈ $4.24 Million	Rs1.29 Billion ≈ $13.96 Million	-48.77pp
2013-03-31	79.11%	Rs1.08 Billion ≈ $11.71 Million	Rs1.37 Billion ≈ $14.80 Million	+1.34pp
2012-03-31	77.77%	Rs1.38 Billion ≈ $14.88 Million	Rs1.77 Billion ≈ $19.13 Million	+77.77pp
2011-03-31	0.00%	Rs25.00K ≈ $270.37	Rs1.61 Billion ≈ $17.44 Million	--

pp = percentage points

About Kilitch Drugs (India) Limited

NSE:KILITCH India Drug Manufacturers - Specialty & Generic

Market Cap

$72.39 Million

Rs6.69 Billion INR

Market Cap Rank

#20566 Global

#1128 in India

Share Price

Rs191.45

Change (1 day)

+1.47%

52-Week Range

Rs124.45 - Rs400.25

All Time High

Rs487.85